This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Caselli, R. J. Articles by Yaari, R. Search for Related Content PubMed Articles by Caselli, R. J. Articles by Yaari, R. Social Bookmarking                         What's this?

Medical Management of Frontotemporal Dementia

Department of Neurology, Mayo Clinic and Arizona Alzheimer's Disease Consortium, Scottsdale, Arizona, caselli.richard{at}mayo.edu

Roy Yaari, MD

Banner Alzheimer's Institute, Phoenix, Arizona

There are no Food and Drug Administration (FDA)-approved medications for the medical management of frontotemporal dementia and its related disorders, so all management recommendations are necessarily off-label and borrowed from experience with Alzheimer's disease, psychiatric disease, and related medical illnesses. Six areas of pharmacotherapeutic consideration are prevention (primary and secondary), intellectual decline, behavioral disorders (such as depression, anxiety, and psychosis), sleep disorders, frequently associated disorders (including motor neuron disease), and abrupt decline. In addition to pharmacotherapy, important lifestyle issues confronting the clinician include driving cessation, securing any weapons maintained at home, assisted living, and caregiver burnout.

Key Words: frontotemporal dementia • dementia and motor neuron disease • pharmacotherapy of dementia

American Journal of Alzheimer's Disease and Other Dementias®, Vol. 22, No. 6, 489-498 (2008)
DOI: 10.1177/1533317507306654


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?